Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Pre-Clinical only!

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Mar 09, 2022 11:39am

111 Views

Post# 34499609

RE:RE:RE:RE:RE:RE:RE:RE:RE:Pre-Clinical only!

Yes but this is the most important thing and the one about which we have zero data. To stay positive you say to yourself that they would not present these results at AACR if they would see absolutely nothing towards a proof of concept in the phase Ia. I mean by that at least stable disease and positive PK/PD data. In the latest articles, they are comparing TH1902 to docetaxel at the MTD of docetaxel alone and see efficacy. So it's hard to believe that patients that got 420 mg/m2 for at least two cycles had no efficacy signs if they were overexpressing sortilin. But again, real tumors in real humans is very different from tumors grafts on mice and you always wonder if docetaxel will be efficacious at higher intracellular concentrations on relapsed cancers with no effective treatment remaining.